QGEN News

Key Factors

Recent Updates

Catalyst

Most analysts rate QGEN Buy or Strong Buy, showing broad institutional optimism.

Risk

Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.
Bearish signals are obviously dominant (4 bearish vs 0 bullish).
Market expectations tend to be pessimistic.

Generated at22:3403/31/2026by

Aime

Newswire

12:41

Parse Biosciences Launches FFPE-Compliant Barcoding Technology for Whole Transcriptome Single-Cell Analysis

13:32

Qiagen's 15min chart triggers MACD Death Cross, Bollinger Bands Narrowing Warning.

14:36

Qiagen's 15-minute chart shows RSI Overbought and KDJ Death Cross signals.

18:29

Qiagen's QuantiFERON Platform Gains Momentum with New Data and AI Investment

15:03

Qiagen's 15min chart shows MACD Death Cross and Bollinger Bands Narrowing.

About QGEN

Charts

SectorLife Science Tools and Services

Established Date--

Listing Date10/01/2018

ExchangeNew York Stock Exchange

Full-time Employees5654

Fiscal Year Ends31/12

Websitewww.qiagen.com

Security TypeCommon stock

Office addressHulsterweg 82, 5912 PL Venlo, The Netherlands

Business

Introduction

Qiagen N.V. is a Dutch holding company whose subsidiary is the main provider of Sample and Assay Technologies. The company is a global leader in "sample to insight" solutions, serving more than 500,000 clients across two broad customer bases: Molecular Diagnostics (Human Healthcare) and Life Sciences (Academia, Pharma R&D and Industrial Applications, primarily Forensic Medicine). The company operates its products in more than 100 countries.